| Literature DB >> 29177100 |
Sally Theobald1, Eleanor E MacPherson2, Laura Dean2, Julie Jacobson3, Camilla Ducker4, Margaret Gyapong5, Kate Hawkins6, Thoko Elphick-Pooley7, Charles Mackenzie8, Louise A Kelly-Hope9, Fiona M Fleming10, Pamela S Mbabazi11.
Abstract
Neglected tropical diseases (NTDs) affect the poorest of the poor. NTD programmes can and should rise to the challenge of playing a part in promoting more gender equitable societies. Gender equity shapes poverty and the experience of disease in multiple ways; yet to date, there has been little attention paid to gender equity in NTD control efforts. Drawing on a synthesis of relevant literature, the tacit knowledge and experience of the authors, and discussions at a meeting on women, girls and NTDs, this analysis paper distills five key lessons from over 20 years of gender mainstreaming in health. The paper links this learning to NTDs and Mass Drug Administration (MDA). Our first lesson is that tailored gender frameworks support gender analysis within research and programming. We present a gender review framework focusing on different MDA strategies. Second, gender interplays with other axes of inequality, such as disability and geographical location; hence, intersectionality is important for inclusive and responsive NTD programmes. Third, gender, power and positionality shape who is chosen as community drug distributors (CDDs). How CDDs interact with communities and how this interface role is valued and practised needs to be better understood. Fourth, we need to unpack the gender and power dynamics at household level to assess how this impacts MDA coverage and interactions with CDDs. Finally, we need to collect and use sex disaggregated data to support the development of more equitable and sustainable NTD programmes.Entities:
Keywords: health systems
Year: 2017 PMID: 29177100 PMCID: PMC5687534 DOI: 10.1136/bmjgh-2017-000512
Source DB: PubMed Journal: BMJ Glob Health ISSN: 2059-7908
Approaches to Mass Drug Administration (MDA) and why gender matters
| Approach to MDA | Data sex disaggregated | Questions for programme managers to consider from a gender perspective |
| House to house | Routinely reported data may be sex disaggregated at community level but frequently not cascaded to national level | Who is chosen to distribute the drugs and why? How are they chosen and who is involved? Are they remunerated? Does this influence who is involved? At what time are drugs distributed? If it is in the evening is it acceptable/does it prompt security concerns? If daytime does this affect the involvement of those who have activities outside the home? Who is available within the household and when? Does CDD gender effect ability to access to household members or enter the home? Does this access also influence individual, household and community adherence? Who has the power to decide whether the medicines are taken or not? Who has the power to provide consent for household members under the age of 18 years? Do power relations at the community level also shape this? |
| Fixed point approaches: health post clinic/distribution point | Routinely reported data may be sex disaggregated at facility level but frequently not cascaded to national level | How and to whom is information communicated about the distribution—how does this reflect the needs of migrants, inhabitants of informal settlements, women, men, people of other genders? How does it reflect the literacy levels? Who is able to attend the distribution? How do livelihoods, gender, power and autonomy affect this? Does the location of distribution points influence distribution of medicines, what is the on impact community coverage or the coverage of any specific group within the community? |
| Child (under 5) health/special events | Routinely reported data not disaggregated at national level, with the possible exception of nutrition | How and to whom is information communicated about the distribution—to what extent does this reflect the needs of women, men, people of other genders migrants, inhabitants of informal settlements? Who is able to attend the distribution? How does livelihoods, gender, power and autonomy affect this? Who has the power to provide consent for the treatment of those under 18 years of age? |
| School-based programmes | Routinely reported data may be sex disaggregated at school level but frequently not cascaded to national level | Who attends school? How is this linked to gender and poverty? How is informed consent negotiated? What happens to those who do not attend school on a regular basis? What happens to those who drop-out of school/do not complete their primary education? |
| Coverage improvement activities | No sex disaggregated information and limited documentation on types of approaches | What are the ‘coverage improvement’ strategies? Who decides on them? What baseline/census material do they relate to and who might be potentially excluded from these? Where appropriate how can we ensure women who are pregnant (and unable to take certain drugs) do access them at a later more appropriate date? |